Theseus Pharmaceuticals Statistics
Total Valuation
| Market Cap | n/a |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 3.24 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.45, with a Debt / Equity ratio of 6.87.
| Current Ratio | 1.45 |
| Quick Ratio | 1.33 |
| Debt / Equity | 6.87 |
| Debt / EBITDA | n/a |
| Debt / FCF | 50.23 |
| Interest Coverage | -3.40 |
Financial Efficiency
Return on equity (ROE) is -98.35% and return on invested capital (ROIC) is -6.94%.
| Return on Equity (ROE) | -98.35% |
| Return on Assets (ROA) | -5.26% |
| Return on Invested Capital (ROIC) | -6.94% |
| Return on Capital Employed (ROCE) | -13.35% |
| Revenue Per Employee | $413,646 |
| Profits Per Employee | -$76,333 |
| Employee Count | 2,300 |
| Asset Turnover | 0.56 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Alteryx has paid $10.00 million in taxes.
| Income Tax | 10.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.67% in the last 52 weeks. The beta is 0.49, so Alteryx's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -15.67% |
| 50-Day Moving Average | 47.74 |
| 200-Day Moving Average | 40.67 |
| Relative Strength Index (RSI) | 76.53 |
| Average Volume (20 Days) | 2,053,387 |
Short Selling Information
The latest short interest is 3.50 million, so 4.79% of the outstanding shares have been sold short.
| Short Interest | 3.50M |
| Short Previous Month | 3.83M |
| Short % of Shares Out | 4.79% |
| Short % of Float | 5.54% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Alteryx had revenue of $970.00 million and -$179.00 million in losses. Loss per share was -$2.52.
| Revenue | 970.00M |
| Gross Profit | 840.00M |
| Operating Income | -146.00M |
| Pretax Income | -169.00M |
| Net Income | -179.00M |
| EBITDA | -110.00M |
| EBIT | -146.00M |
| Loss Per Share | -$2.52 |
Balance Sheet
The company has $725.00 million in cash and $1.31 billion in debt, giving a net cash position of -$581.00 million.
| Cash & Cash Equivalents | 725.00M |
| Total Debt | 1.31B |
| Net Cash | -581.00M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 190.00M |
| Book Value Per Share | 2.63 |
| Working Capital | 372.00M |
Cash Flow
In the last 12 months, operating cash flow was $29.00 million and capital expenditures -$3.00 million, giving a free cash flow of $26.00 million.
| Operating Cash Flow | 29.00M |
| Capital Expenditures | -3.00M |
| Free Cash Flow | 26.00M |
| FCF Per Share | n/a |
Margins
Gross margin is 86.60%, with operating and profit margins of -15.05% and -18.45%.
| Gross Margin | 86.60% |
| Operating Margin | -15.05% |
| Pretax Margin | -17.42% |
| Profit Margin | -18.45% |
| EBITDA Margin | -11.34% |
| EBIT Margin | -15.05% |
| FCF Margin | 2.68% |
Dividends & Yields
Alteryx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Alteryx is $48.98, which is 1.49% higher than the current price. The consensus rating is "Buy".
| Price Target | $48.98 |
| Price Target Difference | 1.49% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Alteryx has an Altman Z-Score of 1.12 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.12 |
| Piotroski F-Score | 2 |